VIIV-HEALTHCARE
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding its application for cabotegravir and rilpivirine long-acting regimen for treatment of HIV-1 infection in virologically suppressed adults.
The reasons given in the CRL relate to Chemistry Manufacturing and Controls (CMC). There have been no reported safety issues related to CMC and there is no change to the safety profile of the products used in clinical trials to date. ViiV Healthcare will work closely with the FDA to determine the appropriate next steps for this New Drug Application.
Cabotegravir is an integrase strand transfer inhibitor developed by ViiV Healthcare and rilpivirine is a non-nucleoside reverse transcriptase inhibitor developed by Janssen Sciences Ireland UC. The cabotegravir and rilpivirine long-acting regimen is an investigational product and not approved anywhere in the world.
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.
For more information on the company, its management, portfolio, pipeline and commitment, please visit www.viivhealthcare.com .
About GSK
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com .
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2018.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The person responsible for arranging the release of this announcement on behalf of GSK is V.A. Whyte, Company Secretary.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191221005008/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wolters Kluwer Ranks First in Dresner 2025 Wisdom of Crowds® Financial Consolidation, Close Management and Financial Reporting Market Study23.10.2025 15:30:00 CEST | Press release
Wolters Kluwer, a global leader in professional information, software solutions and services, today announced that its CCH® Tagetik Intelligent Platform has achieved the top position in the Dresner Advisory Services 2025 Wisdom of Crowds® Financial Consolidation, Close Management and Financial Reporting (FCCR) Market Study. This marks the second straight year that Wolters Kluwer has earned the study’s number one ranking. Access the Dresner Advisory Services 2025 Wisdom of Crowds® Financial Consolidation, Close Management and Financial Reporting (FCCR) Market Study. This study is part of Dresner Advisory Services’ ongoing research into the enterprise performance management (EPM) space and focuses specifically on performance management capabilities targeted at the finance function, including financial consolidation, close management and financial reporting. The study also identifies user trends, priorities, adoption patterns, and vendor performance, helping organizations make informed de
Crexendo and NUSO Partner to Deliver Global Cloud Communications Capabilities23.10.2025 15:15:00 CEST | Press release
NUSO, a leading provider of cloud communications service delivery, today announced it has been chosen by Crexendo®, Inc. (NASDAQ:CXDO), an award-winning software technology company that is a premier provider of cloud communication platform software and unified communication as a service (UCaaS) offerings, including voice, video, contact center, and managed IT services tailored to businesses of all sizes, to be a preferred carrier for the Crexendo cloud communications platform. The expanded partnership allows Crexendo platform licensees to offer cloud communications capabilities over NUSO’s global delivery network, unlocking new revenue opportunities for service providers. With NUSO’s carrier footprint in more than 40 countries, the Crexendo platform now offers global service delivery with industry-leading call quality, uptime, and emergency calling compliance. Platform providers can now offer global service delivery to over 6 million end users worldwide who rely on Crexendo’s Netsapien
SK pharmteco Boosts Domestic Peptide Scale-Up with Investment in California Facility23.10.2025 15:03:00 CEST | Press release
Expansion leverages proprietary chromatography expertise to overcome purification bottlenecks and secure domestic API manufacturing capacity SK pharmteco, a global contract development and manufacturing organization (CDMO), announced today a $6.1 million investment in its Rancho Cordova facility to expand and equip a new lab and CGMP-Kilo-scale facility for Solid-Phase Peptide Synthesis (SPPS) and purification. This expansion, combined with SK pharmteco’s industry-leading chromatography expertise and existing development and manufacturing capabilities in the United States, positions the company to meet the rising demand for U.S. peptide development and domestic clinical and commercial manufacturing. "The investment in our California facility represents a key milestone in our strategic growth and demonstrates an unwavering dedication to the domestic biopharma sector,” said Joerg Ahlgrimm, CEO of SK pharmteco. “Peptides are a vital and rapidly advancing therapeutic category. This project
Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference23.10.2025 15:00:00 CEST | Press release
- Data presented on outcomes following treatment with CFTR modulators add to growing body of evidence that reduced level of sweat chloride is associated with improved clinical outcomes, particularly in younger people with cystic fibrosis - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with CFTR modulators, including the Company’s most recently approved medicine, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), at the North American Cystic Fibrosis Conference (NACFC) held from October 22-25 in Seattle, Washington. Several of the abstracts that will be presented at this year’s conference demonstrate that improvement in CFTR function, as measured by reduction in sweat chloride (SwCl), is associated with improved outcomes in people with cystic fibrosis (CF). ALYFTREK has shown greater reductions in sweat chloride compared to TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor
Boomi Recognized as an Exemplary Vendor in the ISG Buyers Guides™ for Data Integration and Master Data Management 202523.10.2025 15:00:00 CEST | Press release
Boomi earns top rankings across product capability, validation, and customer experience in dual Buyers Guides from ISG Software Research Boomi™, the leader in AI-driven automation, today announced it has been named an Exemplary Vendor in both the ISG Buyers Guide™ for Data Integration and the ISG Buyers Guide™ for Master Data Management 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023515342/en/ Boomi Recognized as an Exemplary Vendor in the ISG Buyers Guides™ for Data Integration and Master Data Management 2025 In these independently published reports from ISG Software Research, a division of ISG (Information Services Group), Boomi was recognized as a Leader across multiple evaluation dimensions, including Product Experience, Capability, Customer Experience, and Validation. Customer Experience and Validation The ISG Buyers Guide™ assessments are widely used by enterprise technology buyers to evaluate market-leadin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom